Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | IGF2R | P11717 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959650 | 1.00 | MAPT (0.70) | MAPTKDM4ERAB9ANPC1L3MBTL1 | |
| SCHEMBL3143837 | 0.83 | RAB9A (1.00) | MAPTKDM4ERAB9ANPC1L3MBTL1 | |
| SCHEMBL3143831 | 0.83 | RAB9A (1.00) | MAPTKDM4ERAB9ANPC1L3MBTL1 | |
| SCHEMBL1956953 | 0.81 | GLA (0.54) | MAPTKDM4ERAB9ANPC1L3MBTL1 | |
| SCHEMBL1956955 | 0.81 | GLA (0.54) | MAPTKDM4ERAB9ANPC1L3MBTL1 | |
| SCHEMBL8400533 | 0.80 | RECQL (0.57) | MAPTEGFRSMN1; SMN2RECQLHIF1A | |
| SCHEMBL8400535 | 0.80 | RECQL (0.57) | MAPTEGFRSMN1; SMN2RECQLHIF1A | |
| SCHEMBL1959904 | 0.77 | SMN1; SMN2 (0.62) | MAPTEGFRSMN1; SMN2RECQLHIF1A | |
| SCHEMBL1959906 | 0.77 | SMN1; SMN2 (0.62) | MAPTEGFRSMN1; SMN2RECQLHIF1A | |
| SCHEMBL1957465 | 0.77 | GCGR (0.48) | MAPTKDM4ERAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | claimed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | claimed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | claimed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | claimed |
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-8697742-B2 | BCRP/ABCG2 inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | ABCC1, ABCB1, BRCA1 | MAPT 3660/4885KDM4E 4298/4885RAB9A 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.